Business Wire

Velodyne Lidar Adds the “Smart” to Blue City Technology’s Smart City Solution

17.7.2020 15:00:00 EEST | Business Wire | Press release

Share

Velodyne Lidar, Inc. today announced a multi-year sales agreement with Blue City Technology, developer of a Smart City system for traffic monitoring. The Blue City Technology solution, equipped with Velodyne’s lidar sensors, helps improve road safety and mobility by providing real-time multi-modal traffic data and analytics to traffic lights.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200717005067/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

The Blue City Technology solution, equipped with Velodyne’s lidar sensors, helps improve road safety and mobility by providing real-time multi-modal traffic data and analytics to traffic lights. (Photo: Blue City Technology)

Blue City Technology, an Automated with Velodyne partner, uses Velodyne Ultra Puck sensors to collect reliable, detailed traffic data about road users, including vehicles, pedestrians and bicyclists, while preserving anonymity. Velodyne’s lidar sensors do not identify individuals’ facial characteristics, a growing concern for civic applications. Lidar has an advantage in privacy over camera-only systems because lidar does not record details like hair and skin color. It is becoming more apparent that adding lidar to traffic systems is adding the “smart” to city traffic and pedestrian infrastructure.

Lidar can scan a large crowd of pedestrians and detect general but critical information such as movement trajectory, whether a child or person has fallen or is acting out of the ordinary, all without disclosing individual features. The Blue City Technology solution monitors roadway intersections so traffic systems can prioritize safe crossing of pedestrians and cyclists and better manage overall vehicle flow. The 360-degree field of view of the Ultra Puck enables the Blue City Technology system to use just one sensor in most cases to cover an entire intersection.

The Blue City Technology solution is deployed in multiple countries, including for traffic monitoring in Montreal and by the city of Kelowna, B.C. as part of a 5G Smart City solution in partnership with Rogers Communications and University of British Columbia. The Kelowna initiative seeks to improve how people move in the downtown area, increasing pedestrian and cyclist safety.

“Velodyne’s lidar sensors are our preferred choice as they are helping us to deliver on our vision to improve the safety and efficiency in road networks,” said Asad Lesani, PhD, Co-founder and CEO, Blue City Technology. “The Velodyne lidar sensors collect traffic data in any weather and lighting conditions, no matter if it’s raining or snowing, or day or night. They allow our solution to help city governments to optimize commute times, and improve safety and planning.”

“Blue City Technology is emerging as a leader in the Intelligent Transportation Systems industry. Their innovative use of Velodyne’s lidar sensors to provide detailed information about traffic networks will enable a new era of smart infrastructure,” said Jon Barad, Vice President of Business Development, Velodyne Lidar. “By generating real-time and accurate detection of road users crossing an intersection and traffic congestion, we believe Blue City will improve peoples’ lives by making traffic systems more intelligent, efficient, safe and effective.”

About Velodyne Lidar

Velodyne provides smart, powerful lidar solutions for autonomy and driver assistance. Headquartered in San Jose, Calif., Velodyne is known worldwide for its portfolio of breakthrough lidar sensor technologies. Velodyne’s founder, David Hall, invented real-time surround view lidar systems in 2005 as part of Velodyne Acoustics. Mr. Hall’s invention revolutionized perception and autonomy for automotive, new mobility, mapping, robotics, and security. Velodyne’s high-performance product line includes a broad range of sensing solutions, including the cost-effective Puck™, the versatile Ultra Puck™, the autonomy-advancing Alpha Prime™, the ADAS-optimized Velarray™, and the groundbreaking software for driver assistance, Vella™.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contact for Velodyne
Landis Communications Inc.
Sean Dowdall
(415) 286-7121
velodyne@landispr.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OPEX® Corporation Introduces the Velo™ Series of Premium Desktop and High Production Document Scanners10.2.2026 11:00:00 EET | Press release

OPEX® Corporation, a global leader in Next Generation Automation providing innovative solutions for warehouse, document and mail automation, has announced the launch of its Velo™ Series powered by InoTec, a new class of premium desktop and free standing high production scanners. The OPEX Velo scanners are engineered to deliver exceptional performance, reliability and image quality and offer industry-standard TWAIN/ISIS connectivity to help simplify deployment into existing capture environments. These state-of-the-art scanners are ideal for service bureaus, government agencies, healthcare providers and enterprise capture operations. “The Velo Series powered by InoTec introduces an entirely new class of scanners to the OPEX portfolio, expanding the options available to both our current customers and organizations considering OPEX for the first time,” said Dann Worrell, President, Document and Mail Automation, OPEX. “By broadening our offerings, we can better align the right solution with

New ZOLL Zenix Monitor/Defibrillator Receives MDR Approval10.2.2026 11:00:00 EET | Press release

ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that Zenix®, the company’s most clinically advanced and easy-to-use professional monitor/defibrillator, is approved under the European Union (EU) Medical Device Regulation 2017/745, commonly referred to as EU MDR. The Zenix monitor/defibrillator is a groundbreaking device that redefines efficiency, clarity, and intelligence in both EMS and hospital settings. Built from years of feedback from customers, Zenix combines intuitive design with powerful functionality to enhance patient care and automate workflows for ease-of-use. Featuring a large, durable touchscreen, Zenix provides critical information when it’s needed. With on-the-fly customization, healthcare professionals can make real-time adjustments, helping them stay in control during high-pressure situations. Equipped with ZOLL’s innovative Real BVM Help® and exclusive Real CPR Help® technology, Zenix gives healthcare pro

IEO and Laife Reply Join Forces to Digitalise the Biobank Through Artificial Intelligence10.2.2026 11:00:00 EET | Press release

The Pathology Division of the European Institute of Oncology (IEO) and Laife Reply, the Reply Group company specialised in AI and Big Data solutions for the healthcare sector, have entered into a collaboration to develop Bianca, the first project in Italy aimed at creating an AI-based digital biobank designed as an integral part of clinical diagnostic practice. The initiative is part of a broader technological innovation journey that structurally integrates research and development into routine diagnostic processes in pathology, transforming the traditional histopathological sample workflow into an end-to-end digital ecosystem. The complete digitalisation of histopathological and molecular diagnostic workflows aims to make analysis more efficient, scalable and reproducible, laying the foundations for the evolution of AI-supported oncological diagnostics. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260210610418/en/ On this

Expereo Elevates expereoOne with New Digital Case Management Capabilities, Delivering Faster, Clearer and More Predictable Service Resolution10.2.2026 11:00:00 EET | Press release

Expereo is redefining what’s possible for global enterprises at CiscoLive Amsterdam with the launch of its enhanced Digital Case Management (DCM) capability in expereoOne. As the world-leading managed Network as a Service (NaaS) provider, Expereo is putting customers firmly in control - slashing resolution times, cutting through operational noise and ensuring everyone is aligned every step of the way. With DCM, service issues are no longer bottlenecks: instead, enterprises experience swift, transparent outcomes, with every stakeholder empowered through a single, real-time view of progress. DCM is designed around a simple objective: enable enterprises to resolve issues faster, with greater clarity and full control, through a fully digital, software-first workflow inside expereoOne. Customers can create, manage and track cases end-to-end within a single platform, ensuring predictable, consistent and aligned service experiences across their global network footprint. Unified, digital-first

U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 110.2.2026 10:15:00 EET | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) and granted Priority Review for oveporexton (TAK-861) for the treatment of narcolepsy type 1 (NT1). Oveporexton is an investigational oral orexin receptor 2 (OX2R)-selective agonist designed to address the underlying orexin deficiency that causes NT1 by restoring orexin signaling. The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date in the third quarter of this calendar year. Takeda remains on track to potentially bring the first approved orexin agonist treatment to people living with NT1. NT1 is a chronic, rare neurological disease caused by a loss of orexin and characterized by excessive daytime sleepiness and cataplexy (sudden loss of muscle tone). This results in a spectrum of physical, cognitive and psychosocial effects that can have a debilitating impact on many aspects of a person’s life, including work, education and social interactio

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye